Medicine and Dentistry
Autoradiograph
7%
B-Cell Lymphoma
12%
Biodistribution
40%
Bispecific Antibody
12%
Cellular Infiltration
24%
Erlotinib
6%
Ex Vivo
13%
Glypican 3
12%
Human Study
12%
Immunocompetent Cell
6%
Lutetium 177
12%
Lymph Node
5%
Lymphatic Tissue
16%
Lymphoid Organ
14%
Malignant Neoplasm
30%
Mesothelin
12%
Monoclonal Antibody
11%
Neoplasm
100%
Non Small Cell Lung Cancer
8%
Onartuzumab
12%
Pembrolizumab
24%
Pharmacokinetics
13%
Positron Emission Tomography
78%
Positron Emission Tomography
14%
Programmed Death 1 Ligand 1
12%
Programmed Death 1 Receptor
13%
Programmed Death-Ligand 1
6%
Radioactive Tracer
23%
Radioimmunotherapy
12%
Radioisotope
12%
Scatter Factor Receptor
12%
Single-Photon Emission Computed Tomography
6%
T Cell
24%
Tetraxetan
5%
Xenograft
5%
Zirconium 89
97%
Keyphrases
227Th
12%
Antibody-based
12%
Autoreactive T Cells
12%
Biodistribution
19%
Bispecific Antibody
12%
Body Response
12%
Cancer Immunotherapy
13%
CD103
12%
Clinical Response
12%
First-in-human Study
12%
Glypican-3 (GPC3)
12%
HCC827
6%
ImmunoPET
12%
Immunotherapeutics
6%
In Cancer
12%
Keyhole Limpet Hemocyanin
5%
Lymph Node
5%
MET Receptor
12%
Non-invasive Approach
12%
Non-invasive Assessment
12%
Onartuzumab
12%
PD-1 Blockade
12%
PD-L1 Expression
6%
Pembrolizumab
12%
Pharmacokinetics
16%
Positron Emission Tomography
42%
Radiopharmaceuticals
12%
Spleen
5%
SUVmax
8%
SUVmean
6%
T Cell Infiltration
24%
Tumor
10%
Tumor Response
6%
Tumor Uptake
27%
Whole-body Distribution
12%
Zirconium-89 (89Zr)
61%
Immunology and Microbiology
Bispecific Antibody
12%
Body Distribution
13%
Cancer Immunotherapy
26%
CD3 Antigen
12%
Cell Infiltration
12%
Cytotoxic T-Cell
13%
Dynamics
14%
Immunotherapy
10%
Keyhole Limpet Hemocyanin
10%
Lymph Node
6%
Lymphoid Tissue
14%
Monospecific Antibody
8%
Mouse
17%
Onartuzumab
12%
Pharmacokinetics
20%
Positron Emission Tomography
65%
Programmed Death 1 Ligand 1
12%
Programmed Death-Ligand 1
12%
T Cell
24%
Xenograft
8%